Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

• Status: Unknown status
• Trial end date: 2020-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a study of HMB plus amino acids in older men with prostate cancer starting androgen deprivation therapy (ADT). The investigators hypothesize that the use of this nutritional supplementation will decrease the loss of muscle mass and strength that occurs when men start ADT.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical College of Wisconsin
• Treatments: Androgens; Ascorbic Acid; Estrogens, Conjugated (USP); Methyltestosterone

Criteria

Inclusion Criteria:

1. Histologically confirmed adenocarcinoma of the prostate

2. Age 60 years or older

3. Patients with asymptomatic or minimally symptomatic PCa for which they are about to start androgen deprivation therapy (ADT) per provider recommendation

• Asymptomatic or minimally symptomatic (as judged by treating physician) metastases allowed

• Men receiving ADT for localized prostate cancer are allowed

4. Patient able to give informed consent.

Exclusion Criteria:

1. Patient already on ADT

2. Patients who are visiting clinic for a second opinion only

3. Patients with a diagnosis of dementia

4. Patients with a diagnosis of a neuromuscular disorder (i.e. multiple sclerosis)